RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 ...
KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...
“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.
Consuming more sugar does not feed cancer cells, but the concern is that it does cause inflammation in the body if you're eating excess sugar in your diet. It is those inflammatory changes that are ...
(RTTNews) - Merck & Co. Inc. (MRK) said Tuesday that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a monotherapy for the first-line treatment of adult patients with ...
RAHWAY, N.J., November 21, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...
The approval was based on data from the phase 3 KEYNOTE-671 trial. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) for the treatment of patients with resectable (tumors ...
The FDA approved pembrolizumab plus platinum-containing chemotherapy as neoadjuvant therapy, followed by single-agent pembrolizumab as adjuvant therapy after surgery for adults with resectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback